NCT06754852View on ClinicalTrials.gov

A Study Assessing HMB-002 in Participants With Von Willebrand Disease

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

February 6, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions
Von Willebrand Disease (VWD)Von Willebrand Disease (VWD), Type 1
Interventions
DRUG

HMB-002 (Part A)

HMB-002 will be administered subcutaneously. Part A will utilize sentinel dosing. The planned duration of study participants in Part A is approximately 12 weeks.

DRUG

HMB-002 (Part B)

HMB-002 will be administered subcutaneously. Part B dosing intervals will be determined following evaluation of Part A results. The planned duration of study participants in Part B will be approximately 21 weeks.

Trial Locations (1)

SE1 1YR

RECRUITING

Richmond Pharmacology, London

All Listed Sponsors
lead

Hemab ApS

INDUSTRY